Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
ImmunoTargets and Therapy is Scopus-indexed (Q3, CiteScore 3.7), WoS ESCI, DOAJ. Published by Dove Medical Press Ltd.
Checked against the index lists dated .
ISSN 2253-1556Verify ISSN ↗
Publisher: Dove Medical Press Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Immunology and Allergy | 145 / 234 | 38th | Q3 |
| Immunology | 155 / 243 | 36th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2015–present, best quartile Q3, CiteScore 3.7.
ImmunoTargets and Therapy is Q3 in Immunology and Allergy (rank 145 of 234) and Q3 in Immunology (rank 155 of 243), by CiteScore 2025.
ImmunoTargets and Therapy is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.7, which places it in quartile Q3 at the 38th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.110, quartile Q2, with an H-index of 36.
The publisher lists an article processing charge of about US$2,320 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
ImmunoTargets and Therapy is published by Dove Medical Press Ltd. Its ISSN is 2253-1556.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
ImmunoTargets and Therapy has an h-index of 48 and a 2-year mean of 5.57 citations per paper (OpenAlex). Its Scopus CiteScore is 3.7, quartile Q3. On 2-year citations it ranks #35 of 231 Scopus journals in Immunology and Allergy.
ImmunoTargets and Therapy published 89 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from China (56%), United States (8.9%) and United Kingdom (3.6%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 1 retracted paper is recorded (2.7 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.